- Home
- ORIC vs KROS Comparison
ORIC vs KROS Comparison
Compare ORIC & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- KROS
- Stock Information
- Founded
- ORIC 2014
- KROS 2015
- Country
- ORIC United States
- KROS United States
- Employees
- ORIC N/A
- KROS 163
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- ORIC Health Care
- KROS Health Care
- Exchange
- ORIC Nasdaq
- KROS Nasdaq
- Market Cap
- ORIC 362.9M
- KROS 558.9M
- IPO Year
- ORIC 2020
- KROS 2020
- Fundamental
- Price
- ORIC $10.31
- KROS $13.35
- Analyst Decision
- ORIC Strong Buy
- KROS Buy
- Analyst Count
- ORIC 8
- KROS 13
- Target Price
- ORIC $18.83
- KROS $20.63
- AVG Volume (30 Days)
- ORIC 1.3M
- KROS 620.1K
- Earning Date
- ORIC 08-11-2025
- KROS 08-06-2025
- Dividend Yield
- ORIC N/A
- KROS N/A
- EPS Growth
- ORIC N/A
- KROS N/A
- EPS
- ORIC N/A
- KROS 0.11
- Revenue
- ORIC N/A
- KROS $214,713,000.00
- Revenue This Year
- ORIC N/A
- KROS $5,006.76
- Revenue Next Year
- ORIC N/A
- KROS N/A
- P/E Ratio
- ORIC N/A
- KROS $123.16
- Revenue Growth
- ORIC N/A
- KROS 91657.70
- 52 Week Low
- ORIC $3.90
- KROS $9.12
- 52 Week High
- ORIC $14.67
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- ORIC 71.78
- KROS 43.06
- Support Level
- ORIC $8.85
- KROS $13.41
- Resistance Level
- ORIC $10.99
- KROS $13.99
- Average True Range (ATR)
- ORIC 0.69
- KROS 0.44
- MACD
- ORIC 0.01
- KROS -0.07
- Stochastic Oscillator
- ORIC 77.10
- KROS 9.84
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.